Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility

FEMS Immunology and Medical Microbiology

Volumn 41, Issue 1, 2004, Pages 27-34

  De Bernardis, Flavia ^a   Tacconelli, Evelina ^b   Mondello, Francesca ^a   Cataldo, Adriana ^b   Arancia, Silvia ^a   Cauda, Roberto ^b   Cassone, Antonio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Biotypes; Candida; HIV; Proteinase inhibitors; Proteinase secretion

Indexed keywords

ASPARTIC PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BIOTYPE; CANDIDA ALBICANS; DRUG EFFECT; FUNGAL STRAIN; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MOUTH CAVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRULENCE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTIC ENDOPEPTIDASES; CANDIDA; CANDIDIASIS, ORAL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LONGITUDINAL STUDIES; MALE; OROPHARYNX; REVERSE TRANSCRIPTASE INHIBITORS; SALIVA; VIRULENCE;

EID: 16544364495     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2003.12.006     Document Type: Article

References (30)

1. Holmberg K., Meyer R.D. Fungal infections in patients with AIDS and AIDS-related complex. Scand. J. Infect. Dis. 18:1986;179-185.
2. Klein R.S., Harris C.A., Butkus Small C., Moll B., Lesser M., Friendland G.H. Oral candidiasis in high risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:1984;354-357.
3. Cutler J.E. Putative virulence factors of Candida albicans. Ann. Rev. Microbiol. 45:1991;187-218.
4. De Bernardis F., Boccanera M., Rainaldi L., Guerra C.E., Quinti I., Cassone A. The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. Eur. J. Epidemiol. 8:1992;362-367.
5. Ollert M.W., Wende C., Gorlich M., McMullan-Vogel C.G., Borg von-Zepelin M., Vogel C.W., Korting H.C. Increased expression of Candida albicans secretory proteinase, a putative virulence factor in isolates from human immunodeficiency virus-positive patients. J. Clin. Microbiol. 33:1995;2543-2549.
6. De Bernardis F., Mondello F., Scaravelli G., Pachì A., Girolamo A., Agatensi L., Cassone A. High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women. J. Clin. Microbiol. 37:1999;1376-1380.
7. Naglick J.R., Rodgers C.A., Shirlaw P.J., Dobbie J.L., Fernandez-Naglick l., Greenspan D., Agabian N., Challacombe S.J. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in human correlates with active oral and vaginal infections. J. Infect. Dis. 188:2003;469-479.
8. Deeks S.G., Smith M., Holodniy I., Kahn J.O. HIV-1 protease inhibitors. A review for clinicians. JAMA. 277:1997;145-155.
9. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Eng. J. Med. 338:1998;853-860.
10. Sepkowitz K.A. Effect of HAART on natural history of AIDS-relate opportunistic disorders. Lancet. 351:1998;228-230.
11. Brodt H.R., Kamps B.S., Gute P., Knupp B., Staszewski S., Helm E.B. Change incidence of AIDS-defining illness in the era of antiretroviral therapy. AIDS. 11:1997;1731-1738.
12. Cassone A., De Bernardis F., Torosantucci A., Tacconelli E., Tumbarello M., Cauda R. In vitro and vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180:1999;448-453.
13. Hube B. Candida albicans secreted aspartyl proteinase. Curr. Top. Med. Mycol. 7:1996;55-69.
14. De Bernardis F., Arancia S., Morelli L., Hube B., Sanglard D., Schaefer W. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particolar SAP2, are virulence factors for Candida vaginitis. J. Infect. Dis. 179:1999;201-208.
15. Cassone A., Tacconelli E., De Bernardis F., Tumbarello M., Torosantucci A., Chiani P. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J. Infect. Dis. 185:2002;188-195.
16. Atzori C., Angeli E., Mainini A., Agostoni F., Micheli V., Cargnel A. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. J. Infect. Dis. 181:2000;1629-1634.
17. Wu T., Wright K., Hurst S.F., Morrison C.J. Enhanced extracellular production of aspartyl proteinase, a virulence factor by Candida albicans isolates following growth in subinhibitory concentration of fluconazole. Antimicrob. Agents Chemother. 44:2000;1200-1208.
18. Cauda R., Tacconelli E., Tumbarello M., Morace G., De Bernardis F., Torosantucci A., Cassone A. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 21:1999;20-25.
19. De Bernardis F., Agatensi L., Ross I.K., Emerson G.W., Lorenzini R., Sullivan P.A., Cassone A. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J. Infect. Dis. 161:1990;1276-1283.
20. Barchiesi F.A., Colombo L., McGough D.A., Fothergill A.W., Rinaldi M.G. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1994;1530-1533.
21. National Committee for Clinical Laboratory Standard (1997). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved Standard M27-A, NCCLS, Wayne, PA.
22. Vollrath D., Davis R.W. Resolution of DNA molecules greater than 5 megabases by contour clamped homogenous electric fields. Nucleic Acids Res. 15:1987;7865-7876.
23. Korting H.C., Schaller M., Eder G., Hamm G., Bohmer U., Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob. Agents Chemoth. Aug. 1999;2038-2042.
24. Munro C.A., Hube B. Antifungal therapy at the HAART of viral therapy. Trends Microb. Opin. 10:2002;173-177.
25. Skrbec D., Romeo D. Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease. Biochem. Biophys. Res. Commun. 297:2002;1350-1353.
26. Bektic J., Lell C.P., Fuchs A., Stoiber H., Speth C., Lass-Florl C., Borg-von Zepelin M., Dierich M.P., Wurzner R. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS, Immun. Med. Microb. 31:2001;65-71.
27. Schaller M., Krnjac N., Niewerth M., Hamm G., Hube B., Korting H. Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans. J. Med. Microb. 52:2003;247-249.
28. Stewart K., Abad-Zapatero C. Candida proteases and their inhibition: prospects for antifungal therapy. Curr. Med. Chem. 8:2001;941-948.
29. Taylor B.N., Fischenbaum C., Saavedra M., Slaviinsky III J., Swoboda R., Wozniak K., Arribas A., Powderly W., Fidel P.L. Jr. In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus. J. Inf. Dis. 182:2000;955-959.
30. Gruber A., Speth C., Lukasser-Vogl E., Zangerle R., Borg-von Zepelin M., Dierich M.P., Wurzner R. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology. 41:1999;227-234.